Bystander or no bystander for gene directed enzyme prodrug therapy.
about
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug TherapyProgress and problems with the use of suicide genes for targeted cancer therapyThe engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of canceriPS-derived MSCs from an expandable bank to deliver a prodrug-converting enzyme that limits growth and metastases of human breast cancersSuicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice.A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replicationDevelopment of an inducible caspase-9 safety switch for pluripotent stem cell-based therapiesTherapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs.Safeguarding nonhuman primate iPS cells with suicide genes.ATRA enhances the bystander effect of suicide gene therapy driven by the specific promoter LEP 503 in human lens epithelial cellsIn vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.Development of a cancer-marker activated enzymatic switch from the herpes simplex virus thymidine kinase.Three-dimensional assessment of bystander effects of mesenchymal stem cells carrying a cytosine deaminase gene on glioma cells.Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).Outflow tract ablation using a conditionally cytotoxic feline immunodeficiency viral vector.Vesicular Stomatitis Virus G Glycoprotein and ATRA Enhanced Bystander Killing of Chemoresistant Leukemic Cells by Herpes Simplex Virus Thymidine Kinase/Ganciclovir.Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC DerivativesEmerging implications of nonmammalian cytosine deaminases on cancer therapeutics.Gene-directed enzyme prodrug therapy.Recombinant horseradish peroxidase variants for targeted cancer treatment.Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice.Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.Combined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition.Bioengineered viral vectors for targeting and killing prostate cancer cellsCytotoxic effect of co-expression of human hepatitis A virus 3C protease and bifunctional suicide protein FCU1 genes in a bicistronic vector.Combined antitumor activity of the nitroreductase/CB1954 suicide gene system and γ-rays in HeLa cells in vitro.The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma.Regulated Mesenchymal Stem Cells Mediated Colon Cancer Therapy Assessed by Reporter Gene Based Optical Imaging.
P2860
Q21261309-6BB7B120-0531-4727-A55C-3662C88CE69EQ24609522-51CAFE70-A780-4DFB-9A94-9958CA97A4C2Q28262370-2F1CD923-EC15-478B-A02C-0D4BFA9991B0Q30689378-7948E141-4408-4549-892C-C18CC6771A44Q33458985-25FD1AEF-62B2-4167-960A-6F6BD789DA13Q33604560-3DC05B01-4392-4EB8-88F1-334759390B2AQ33790492-1361D3E8-F00B-44F4-BF2A-1D6FDE475574Q34044181-B39FDEB7-0B29-46EF-B526-D762E7A53793Q35176800-3F7F51AF-6C64-418C-B2A7-5F6A620794F5Q35201410-5C509ADC-6061-43D3-99A0-2E4D6A0F92F6Q35238279-5E48EFBB-120D-4B13-B818-6034D1BDC3C1Q36145952-38C08064-BC23-49DE-AAB2-F4DD35D45A79Q36176245-94133549-36E1-4418-9949-1F75F74D2C9FQ36227090-7BB357D2-D6DD-4A8A-B14F-956BF23DAE90Q36250616-9D8C0AC8-2FAE-4952-8624-E310EDB193E2Q36640056-CEF77D8B-34DC-46AF-9205-748B1E2F70F2Q37593014-C27866E6-F42A-4B00-8D4F-6F885039F549Q37684212-1275686D-D67D-408D-AD5E-B34499E918FAQ37707825-EDE80830-19FF-4638-87D5-BED80FEE53A6Q38016754-4DB74EEF-F6DC-4E2E-9736-9611501E232AQ38262019-B69A3903-DA2F-49B8-A21B-07A3BDA05C27Q38785216-00A57FEF-DED4-40B4-A328-E06E74101EACQ39033552-37470A8F-716C-44D3-A0B2-4B9228CC0E24Q39432031-9BA795F0-180C-4C64-BD84-8F7B89C8C3C1Q39465544-41A20E3C-452A-4DF4-AF89-79727766C92EQ39507151-45206149-B0A4-480F-B071-687D594AC4C3Q39556636-1E18CCD5-2B73-4C1E-BEA8-DA9B1C6CC1E2Q39590965-24FF27A5-9A7C-47BD-8DE4-FF36EBD1BA87Q40106600-CEE50000-DCC9-46A0-A508-CAB31D93BC92Q42029049-CFDAC320-679A-4F32-8130-8A98AC0DB3CEQ45362340-DADCB274-6E27-43B1-B798-2863405B1370Q52628020-EA3BF6CF-768C-44BD-A464-618D2C5C64A2
P2860
Bystander or no bystander for gene directed enzyme prodrug therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Bystander or no bystander for gene directed enzyme prodrug therapy.
@en
Bystander or no bystander for gene directed enzyme prodrug therapy.
@nl
type
label
Bystander or no bystander for gene directed enzyme prodrug therapy.
@en
Bystander or no bystander for gene directed enzyme prodrug therapy.
@nl
prefLabel
Bystander or no bystander for gene directed enzyme prodrug therapy.
@en
Bystander or no bystander for gene directed enzyme prodrug therapy.
@nl
P2093
P1433
P1476
Bystander or no bystander for gene directed enzyme prodrug therapy
@en
P2093
Dean C Singleton
Gabi U Dachs
Michelle A Hunt
Sophie Syddall
P304
P356
10.3390/MOLECULES14114517
P407
P577
2009-11-10T00:00:00Z